Home Monitoring vs. Traditional Care in CF: Year-Long Study Results
A study of home monitoring vs. traditional cystic fibrosis care in 267 patients age fourteen and older showed that after […]
Lung Clearance Index Improved in Children Ages 6-11 on Ivacaftor/Lumacaftor
Ivacaftor/Lumacaftor Improves Lung Clearance Index Score In Children A new phase 3 study, led by The Hospital for Sick Children […]
Outcomes and Tolerances in Cystic Fibrosis Treatment Lumacaftor/Ivacaftor
Last month, the results of a study were published that looked at the progress and side effects of the cystic […]
Full-Fat Fermented Dairy May Cause Less Inflammation Than Regular Dairy
In the cystic fibrosis diet, dairy products are often used to reach high-calorie targets, and new research has shown that […]
Orkambi Study On Children Age 6-12 With DDF508: Cystic Fibrosis Treatment
Results are in from a 24-week study of Orkambi (lumacaftor/ivacaftor – a medication used in cystic fibrosis treatment) in 58 children […]
Risk of Hearing Loss from IV Aminoglycosides in Cystic Fibrosis
Cumulative exposure to IV tobramycin and amikacin, which are critical for treating cystic fibrosis infections, increases the risk of hearing […]
Treatment for Cystic Fibrosis: Vertex Acquires Concert’s CFTR Potentiator CTP-656
Vertex Pharmaceuticals recently purchased the Phase 2 cystic fibrosis potentiator drug CTP-656 from Concert Pharmaceuticals. The deal is estimated to […]
Respiratory Health and Air Pollution
The impact of small particle air pollution on the lower airways (lungs) has long been studied, but now scientists have […]
Does Ivacaftor Affect Lung Bacteria in Cystic Fibrosis?
Ivacaftor has been shown to increase CFTR activity and lung function in people with Cystic Fibrosis and the G551D mutation, […]
Research on CF and Exercise in Cystic Fibrosis treatment
Significant research, both recent and decades old, shows that exercise helps people with CF. Yet it’s not always a part […]